Akoya Biosciences, Inc. (AKYA) Q3 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals several negative indicators: a reduced revenue outlook, continued customer spending pressure, and regulatory delays. Despite some operational improvements, financial metrics show significant declines in revenue and instrument sales. The Q&A section highlights concerns over cash flow, strategic uncertainties, and competitive pressures. Although there are some positive aspects, such as gross margin improvements and a focus on shareholder value, the overall sentiment leans negative due to the challenging market environment and financial constraints.
Key Financial Performance
Total Revenue $18.8 million, a 25% year-over-year decrease due to ongoing capital equipment purchase constraints in the life sciences tools market.
Instrument Revenue $5.7 million, a 53% year-over-year decrease, driven by the placement of 35 instruments in the quarter compared to 51 in the second quarter.
Reagent Revenue $6.3 million, an 11% year-over-year increase, attributed to a growing installed base and increased utilization.
Services and Other Revenue $6.5 million, a 10% year-over-year decrease, primarily due to underperformance in instrument sales.
Gross Margin 62.3%, an improvement from 60.6% in the prior year period, resulting from operational efficiencies and a fully operational manufacturing center-of-excellence.
Operating Expenses $20.1 million, a 25% year-over-year decrease, due to cost improvement efforts implemented throughout the year.
Loss from Operations $8.3 million, a 28% improvement over the $11.6 million loss in the prior year period, reflecting reduced operating expenses.
Cash Position Approximately $39.3 million in cash, cash equivalents, and marketable securities as of September 30, 2024.
Installed Base of Instruments 1,299 instruments, a 15% increase over the prior year period.
PhenoCycler Fusions (PCF) 251 units in the field, supporting high-plex tissue analysis.
PhenoImager HT Systems 376 units in the field, positioned for regulatory approval.
Publications Citing Platform Technologies 1,578 publications, a 47% increase from the prior year.
Operating Highlights
New Product Launches: Akoya introduced the PhenoCode IO60 panel, an immuno-oncology solution covering 60 key protein biomarkers, and a new 24-plex mouse panel optimized for preclinical applications.
Reagent Product Offerings: Expanded the PhenoCode catalog of molecular barcodes to enable routine Ultrahigh Plex 100 biomarker spatial experiments.
Market Expansion: Akoya's platforms were chosen for a large multi-institutional study titled MANIFEST, aimed at understanding patient responses to cancer immunotherapy.
Partnerships: Announced partnerships with the Francis Crick Institute and Royal Marsden NHS Foundation Trust for the MANIFEST study.
Operational Efficiencies: Implemented a more operationally-efficient cost structure and a manufacturing center-of-excellence, leading to improved gross margins.
Installed Base Growth: Total installed base increased to 1,299 instruments, a 15% increase year-over-year.
Strategic Shifts: Evaluating a range of strategic alternatives to identify the best path forward for sustainable growth and profitability.
Risk or Challenges
Revenue Expectations: Revenue for the third quarter came in below expectations due to ongoing capital equipment purchase constraints in the life sciences tools market. Full year revenue is now expected to be in the range of $80 million to $85 million, down from a prior range of $96 million to $104 million.
Capital Equipment Funding: There is continued pressure on customer spending, particularly in North America, which has been attributed to extended sales cycles and limited capital equipment funding.
Sales Cycle Volatility: Sales cycles have increased by approximately 35% compared to the previous year, leading to challenges in predictability and conversion rates.
Operational Restructuring: The organizational restructuring, while necessary for long-term efficiency, has temporarily disrupted operations and contributed to the shortfall in instrument sales.
Market Competition: Increased competition in the spatial biology market, particularly from companies like Lunaphore, has been noted, although the primary challenge remains the macroeconomic environment.
Cash Flow Breakeven: The company does not expect to achieve cash flow breakeven by the end of 2024, with expectations now set for mid-2025.
Strategic Alternatives: The company is actively evaluating a range of strategic alternatives to ensure sustainable growth and profitability, with no options off the table.
Service Revenue Decline: Service and other revenue decreased by 10% year-over-year, primarily due to underperformance in instrument sales.
Regulatory and Economic Factors: The company is closely monitoring regulatory changes and economic factors that could impact funding and spending in the life sciences sector.
Guidance & Outlook
Revenue Guidance: Expect full year revenue in the range of $80 million to $85 million, with a minor step-up in fourth quarter revenue.
Operational Efficiency: Implemented a more operationally-efficient cost structure and a manufacturing center-of-excellence, improving margins.
Companion Diagnostic Pipeline: Advancing companion diagnostic pipeline expected to contribute significantly to growth and value in the near-term.
New Product Offerings: Introduced new reagent product offerings including the PhenoCode IO60 panel and a 24-plex mouse panel.
Strategic Alternatives: Actively evaluating a range of strategic alternatives for sustainable growth and profitability.
Revenue Expectations: Full year revenue expected to be in the range of $80 million to $85 million.
Gross Margin: Gross margin improved to 62.3%, with expectations for continued expansion.
Cash Flow Breakeven: Expect to achieve cash flow breakeven in mid-2025.
Adjusted EBITDA: Expect adjusted EBITDA in the low single-digits by the end of the year.
Shareholder Return Plan
Shareholder Return Plan: Akoya is actively evaluating a range of strategic alternatives to identify the best path forward for sustainable growth, profitability, and long-term success, which includes maximizing shareholder value.
Cash Position: As of September 30, 2024, Akoya ended the quarter with approximately $39.3 million in cash, cash equivalents, and marketable securities.
Revenue Guidance: For the full year 2024, Akoya expects revenue in the range of $80 million to $85 million, down from a prior range of $96 million to $104 million.
Operating Expenses: Operating expenses were reduced to $20.1 million in Q3 2024, a 25% decrease compared to the prior year period.
Loss from Operations: Loss from operations was $8.3 million in Q3 2024, a 28% improvement over the $11.6 million loss in the prior year period.
Cash Burn: Cash burn for Q3 was in the range of $8 million to $9 million, with expectations for a meaningful reduction in Q4.
Strategic Focus: Akoya's priorities include implementing platform improvements, advancing clinical trial partnerships, and achieving profitability goals.
Key Q&A
Earnings Word Cloud
AKYA Transcript
The earnings call summary reveals several negative indicators: a reduced revenue outlook, continued customer spending pressure, and regulatory delays. Despite some operational improvements, financial metrics show significant declines in revenue and instrument sales. The Q&A section highlights concerns over cash flow, strategic uncertainties, and competitive pressures. Although there are some positive aspects, such as gross margin improvements and a focus on shareholder value, the overall sentiment leans negative due to the challenging market environment and financial constraints.
The earnings call presented a mixed outlook. Positive aspects include significant revenue growth, improved gross margins, and reduced operating losses. However, the lack of shareholder return plans, workforce reductions, and competitive pressures weigh negatively. The Q&A revealed cautious guidance and unresolved questions about cash burn and restructuring impact. The company's focus on achieving cash flow break-even by 2024, without immediate shareholder returns, suggests a cautious market reaction. Given the absence of market cap data, a neutral sentiment is prudent, reflecting balanced positive and negative factors.
The earnings call reveals strong financial performance with record revenue growth and optimistic guidance for future margin improvements. The Q&A section highlights strategic partnerships and expected growth in reagents, supporting an optimistic outlook. Despite some macroeconomic pressures, the company's strategic focus on less impacted areas and new product developments bolster confidence. The projected breakeven in operating cash flow further enhances the positive sentiment. However, lack of detailed guidance in some areas tempers expectations slightly, leading to a positive but not strong positive rating.
The earnings call summary indicates strong financial performance with 34% revenue growth, improved gross margins, and effective cost management. Despite competitive pressures and regulatory risks, the company is expanding its product offerings and market reach. The Q&A session revealed positive sentiment, with management addressing concerns and providing optimistic guidance. Although RNA chemistry capabilities are delayed, the overall outlook remains strong, with expectations for further growth and margin improvements. The lack of explicit 2024 guidance is mitigated by thematic insights, maintaining a positive sentiment.
AKYA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
